Dyne Therapeutics Secures $400M Expanded Debt Facility with Hercules Capital
Event summary
- Dyne Therapeutics expanded its debt facility with Hercules Capital to up to $400 million, including $50 million in immediate funding.
- The amendment adds $50 million in milestone-based borrowing and $75 million in discretionary funding.
- Total borrowed under the facility now stands at $200 million with $200 million in potential future funding.
- Proceeds will support potential U.S. launches of z-rostudirsen (DMD) and z-basivarsen (DM1) within two years.
The big picture
This expanded debt facility reflects Hercules Capital's confidence in Dyne's pipeline and positions the company for critical regulatory and commercial milestones. The non-dilutive financing provides flexibility as Dyne prepares for potential approvals of its lead candidates in Duchenne muscular dystrophy and myotonic dystrophy type 1. The deal underscores the growing reliance on specialized lenders for late-stage biotech companies navigating expensive clinical and launch phases.
What we're watching
- Execution Risk
- Whether Dyne can meet milestones to access the full $400 million facility.
- Regulatory Milestones
- The pace at which z-rostudirsen and z-basivarsen advance through FDA approval processes.
- Commercialization Strategy
- How Dyne allocates capital to support two potential U.S. launches within two years.
Related topics